share_log

Eli Lilly and Co | PRE 14A: Preliminary proxy statements relating to merger or acquisition

SEC announcement ·  Mar 8 16:36
Summary by Moomoo AI
Eli Lilly and Company (Lilly) announced a series of significant achievements and strategic decisions in its 2023 Annual Meeting of Shareholders notice. The company reported regulatory approvals for new medicines, including Omvoh for ulcerative colitis, Jaypirca for MCL or CCL, and Zepbound for obesity. Lilly also highlighted results from the Trailblazer-ALZ 2 study indicating a slowdown in Alzheimer's disease progression. The company delivered strong shareholder returns through share price appreciation and dividends and donated over $4 billion in medicines to charitable organizations. Lilly's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030. The company engaged with investors on topics like drug pricing, global product access, and environmental, social, and governance issues. Management proposals at the 2024 annual meeting will include eliminating the classified board structure and supermajority voting requirements in the articles of incorporation. The 2024 Annual Meeting of Shareholders will be held virtually on May 6, 2024, at 8:30 a.m. EDT.
Eli Lilly and Company (Lilly) announced a series of significant achievements and strategic decisions in its 2023 Annual Meeting of Shareholders notice. The company reported regulatory approvals for new medicines, including Omvoh for ulcerative colitis, Jaypirca for MCL or CCL, and Zepbound for obesity. Lilly also highlighted results from the Trailblazer-ALZ 2 study indicating a slowdown in Alzheimer's disease progression. The company delivered strong shareholder returns through share price appreciation and dividends and donated over $4 billion in medicines to charitable organizations. Lilly's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030. The company engaged with investors on topics like drug pricing, global product access, and environmental, social, and governance issues. Management proposals at the 2024 annual meeting will include eliminating the classified board structure and supermajority voting requirements in the articles of incorporation. The 2024 Annual Meeting of Shareholders will be held virtually on May 6, 2024, at 8:30 a.m. EDT.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more